
A single injection of the monoclonal antibody (mAb), adintrevimab prevented COVID-19 in the phase 2/3 EVADE trial, finds a study yesterday in Open Forum Infectious Diseases.
The randomized controlled trial measured outcomes among 2,582 vaccine-naive participants ages 12 years and older who received either a single 300-milligram intramuscular injection of adintrevimab or placebo. Safety was assessed during 6-month follow-up, and the primary end point was symptomatic COVID-19 infection within 28 days and through 3 months. The study was conducted from April 27, 2021, through January 11, 2022.
The relative risk reduction (RRR) for participants who received an injection as post-exposure prophylaxis (PEP) was 74.9%. When injected as part of pre-exposure prophylaxis (PrEP), the RRR was 71.1%.
In 428 PrEP participants who were randomized to receive the injection after emergence of the Omicron variant, adintrevimab reduced RT-PCR-confirmed symptomatic COVID-19 by 40.6%.
Adintrevimab is derived from a survivor of the 2003 SARS-CoV epidemic and engineered for improved potency and broad neutralization against SARS-CoV-2 and other SARS-like coronaviruses with pandemic potential, the authors said. There were no serious side effects reported during the study.
These data support continued development of mAbs for prevention of COVID-19, particularly for vulnerable populations.
"These data support continued development of mAbs for prevention of COVID-19, particularly for vulnerable populations that may not be protected through vaccination," the authors said. "These data may have the potential to support accelerated development of future mAbs engineered from adintrevimab or utilizing the adintrevimab antibody scaffold."